Olanzapine enabled rechallenge after lorlatinib‐induced psychosis: A case report
Olanzapine enabled rechallenge after lorlatinib‐induced psychosis: A case report
About this item
Full title
Author / Creator
Publisher
Australia: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
Australia: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
Lorlatinib is a third-generation tyrosine kinase inhibitor for anaplastic lymphoma kinase (
)-positive non-small cell lung cancer (NSCLC). While it has a high intracranial lesion control rate, it can also cause central nervous system complications, including psychotic symptoms. We present a case of lorlatinib-induced psychosis successfully manag...
Alternative Titles
Full title
Olanzapine enabled rechallenge after lorlatinib‐induced psychosis: A case report
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_12034264
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_12034264
Other Identifiers
ISSN
2769-2558
E-ISSN
2769-2558
DOI
10.1002/pcn5.70091
